Efficacy of lemborexant on sleep quality and neurocognitive outcomes among hospital rotating shift workers: A randomized, double-blind, placebo-controlled trial.
Tipvilai Taweepunturat, Abisith Dechachongjumroen, Pasiri Sithinamsuwan et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized, double-blind, placebo-controlled trial evaluated the effects of lemborexant 5 mg on sleep quality and neurocognitive outcomes in rotating shift workers aged 20 to 60 years. The study found significant improvements in cognitive function, inflammatory biomarkers, and health-related quality of life, with all participants completing the 6-week follow-up. Notably, LEM5 improved MoCA and DSST scores (all p < 0.001).
Key findings
- LEM5 significantly improved MoCA and DSST scores (all p < 0.001).
- Significant reductions in IL-6 and CRP levels were observed with LEM5.
- Actigraphy showed persistent benefits in total sleep time and sleep efficiency over 42 days.
- Health-related quality of life scores improved significantly with LEM5.
Why it matters
The findings suggest that lemborexant may effectively address sleep disorders and cognitive impairments in rotating shift workers, a population at high risk for sleep-related issues. Improved sleep quality and cognitive function can enhance overall health and job performance in this demographic.